978 related articles for article (PubMed ID: 3488026)
1. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
2. Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.
Saijo N; Ozaki A; Sakurai M; Ishihara J; Takahashi H; Sasaki Y; Hoshi A; Hamburger AW
Jpn J Cancer Res; 1986 May; 77(5):487-93. PubMed ID: 3089980
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
6. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
7. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
8. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
Schwarz RE; Vujanovic NL; Hiserodt JC
Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
[TBL] [Abstract][Full Text] [Related]
12. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
17. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]